CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 37 enrolled
Drug / intervention
20mg lurasidone +3 moredrug
Likely dose
20mg lurasidonefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02174510
NCT02174510Phase 1Completed
CompareCT.gov

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Sumitomo Pharma (Suzhou) Co., Ltd.·interventional·Posted Jun 25, 2014·Updated Jan 11, 2019

In Brief

A Phase 1 clinical trial evaluating 20mg lurasidone, 40mg lurasidone, and 2 other interventions for Schizophrenia. Completed, enrolled 37 participants across 1 site.

Detailed Summary

To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects. To evaluate the safety and tolerability of lurasidone after single oral administration of different doses in healthy Chinese subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesChina
CollaboratorsXuhui Central Hospital, Shanghai

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 25, 2014
Enrollment StartMar 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.0 years ago

Interventions

20mg lurasidonedrug

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

40mg lurasidonedrug

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

80mg lurasidonedrug

single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

placebodrug